Crinetics Pharmaceuticals to Participate in September Investor Conferences


SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

 Baird Global Healthcare Conference
Date:  Wednesday, September 9th 2020
Time:  12:50 pm Eastern Time
Presenter: Scott Struthers, Founder & CEO
 H.C. Wainwright: 22nd Annual Global Investment Conference
Date:  Monday, September 14th 2020
Time:  10:30 am Eastern Time
Presenter: Scott Struthers, Founder & CEO
 Cantor Fitzgerald Global Healthcare Conference 
Date:  Tuesday, September 15th 2020
Time:  2:00 pm Eastern Time
Presenter: Scott Struthers, Founder & CEO

Webcast Links:

Links to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page in the Investors section on the Company’s website at crinetics.com.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing an oral nonpeptide somatostatin receptor type 5 (sst5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit crinetics.com.


Contact:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464

Media:
Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(858) 450-6464

Source: Crinetics Pharmaceuticals, Inc.